GLP-1/glucagon dual-acting agonist (obesity / diabetes)

Our partner Boehringer Ingelheim has initiated two Phase 1 trials in 2017 with a GLP-1/glucagon agonist and a long-acting amylin analog. Potential for once-weekly administration for the treatment of obesity and/or type 2 diabetes.

The dual-acting GLP-1/glucagon agonist activates both the GLP-1 and glucagon receptors, two key gut hormone receptors, and may offer better blood glucose and weight loss control than currently available single-agonist treatments. The compound builds partly on the effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans.

Amylin is a pancreatic peptide hormone that plays an important role in decreasing food intake and in the regulation of postprandial plasma glucose levels. The compound is a long-acting analog of amylin is looking into weight loss in preclinical models of obesity.

2017 achievements and next step

The clinical development of the dual-acting GLP-1/ glucagon agonist and the long-acting amylin analog is randomized, double-blind, first-in-human studies to evaluate the safety and tolerability of single ascending doses in healthy subjects.

Results are expected late 2018 for both trials.

Collaboration with Boehringer Ingelheim

Zealand has two collaborations with Boehringer Ingelheim, where they funds all research, development and commercialization activities. Zealand is eligible to receive royalties and milestone payments as follows:

GLP-1/glucagon dual-acting agonist (2011 agreement)

  • EUR 365 million outstanding in milestone payments
  • High single-digit to low double-digit percentage royalties on global sales